CHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader in artificial intelligence-driven precision cardiovascular medicine tests, today announced the publication of its groundbreaking study in the Journal of the American Heart Association (JAHA), an official journal of the American Heart Association.

芝加哥-（商业线）-人工智能驱动的精确心血管药物测试领导者Cardio Diagnostics Holdings，Inc。（纳斯达克股票代码：CDIO）今天宣布在“美国心脏协会杂志”（JAHA），美国心脏协会的官方杂志。

This study, conducted in collaboration with Intermountain Healthcare and University of Iowa Hospitals and Clinics, describes the development and validation of PrecisionCHD, a pioneering artificial intelligence-guided integrated genetic-epigenetic test for detecting coronary heart disease (CHD)..

这项研究与Intermountain Healthcare和爱荷华大学医院和诊所合作进行，描述了PrecisionCHD的开发和验证，PrecisionCHD是一种开创性的人工智能引导的综合遗传表观遗传学检测方法，用于检测冠心病（CHD）。。

The article entitled 'The Validation of an Integrated Genetic-Epigenetic Test for the Assessment of Coronary Heart Disease,' unveils a significant leap in CHD diagnosis. Traditional diagnostic methods for CHD are often invasive, require exposure to ionizing radiation, and are not widely accessible due to the need for specialized infrastructure.

题为“用于评估冠心病的综合遗传-表观遗传学检测的验证”的文章揭示了冠心病诊断的重大飞跃。冠心病的传统诊断方法通常是侵入性的，需要暴露于电离辐射，并且由于需要专门的基础设施而无法广泛使用。

Furthermore, some of the tests are not sensitive to all forms of CHD and can be very costly. As a result, millions of Americans do not receive adequate and potentially lifesaving cardiac care in a timely manner. With the introduction of PrecisionCHD, clinicians now have a powerful, scalable, non-invasive alternative, in the form of a blood-based test that uses artificial intelligence (AI) and personalized genetic and epigenetic information to sensitively detect the presence of CHD..

此外，某些测试对所有形式的冠心病都不敏感，并且可能非常昂贵。结果，数百万美国人没有及时获得足够的和可能挽救生命的心脏护理。随着PrecisionCHD的引入，临床医生现在以基于血液的测试形式提供强大，可扩展，非侵入性的替代方案，该测试使用人工智能（AI）以及个性化的遗传和表观遗传信息来灵敏地检测CHD的存在。。

The study detailed in JAHA, conducted by researchers from Cardio Diagnostics, Intermountain Healthcare and the University of Iowa Hospitals and Clinics, describes the development and validation of the PrecisionCHD test in three independent cohorts totaling 2,516 individuals. PrecisionCHD is the first integrated genetic-epigenetic test for the detection of CHD that uses the input from six methylation sensitive digital PCR (MSdPCR) assessments to determine the presence or absence of CHD..

JAHA中详细介绍的研究由Cardio Diagnostics，Intermountain Healthcare和爱荷华大学医院和诊所的研究人员进行，描述了PrecisionCHD测试在三个独立队列中的开发和验证，共计2516人。PrecisionCHD是第一个用于检测CHD的综合遗传-表观遗传学检测，它使用六种甲基化敏感数字PCR（MSdPCR）评估的输入来确定CHD的存在与否。。

The article details the mapping of each of these MSdPCR assays to distinct modifiable drivers of CHD through which clinicians are able to gain personalized insights into each patient’s CHD presentation. In addition, the article notes that because methylation is dynamic, clinicians can consider focused re-testing to determine the effectiveness of CHD therapy.

本文详细介绍了这些MSdPCR检测方法中的每一个与冠心病不同的可修改驱动因素的映射，通过这些驱动因素，临床医生可以获得对每位患者冠心病表现的个性化见解。此外，文章指出，由于甲基化是动态的，临床医生可以考虑重点重新测试以确定CHD治疗的有效性。

Robert Philibert MD Ph.D., lead author and Chief Medical Officer of Cardio Diagnostics, stated that “this is a game changer for Personalized Cardiovascular Care” and noted that “unlike other methods of CHD testing, there is no exposure of patients to ionizing radiation or potentially kidney damaging contrast dye.” Dr.

Cardio Diagnostics的主要作者兼首席医疗官Robert Philibert博士表示，“这是个性化心血管护理的游戏改变者”，并指出“与其他冠心病检测方法不同，患者不会接触电离辐射或潜在的肾脏损伤对比染料“。

Philibert added, “What's truly revolutionary about this approach is its ability to provide a more comprehensive, personalized snapshot of a patient's CHD drivers, allowing for early intervention and tailored treatment plans. This is personal for me; seeing patients who previously had limited options for early diagnosis now have access to this state-of-the-art technology is a milestone in cardiac care.”.

菲利伯特补充说，“这种方法真正革命性的是它能够提供患者冠心病驱动程序的更全面，个性化的快照，允许早期干预和量身定制的治疗计划。这对我来说是个人的；看到以前早期诊断选择有限的患者现在可以使用这种最先进的技术是心脏护理的一个里程碑“。

The implications of this research are particularly relevant for rural healthcare, where access to specialized medical facilities and diagnostics is often limited. Americans in rural communities have limited access to specialized medical facilities, fewer healthcare providers, and often, travel far greater distances for medical care.

这项研究的意义特别适用于农村医疗保健，那里获得专门的医疗设施和诊断往往是有限的。农村社区的美国人获得专业医疗设施的机会有限，医疗服务提供者较少，而且往往要走更远的距离进行医疗护理。

Because the PrecisionCHD test requires only a simple blood draw, patients in underserved areas will now have access to state-of-the-art cardiac assessments..

由于PrecisionCHD测试只需要简单的抽血，服务不足地区的患者现在可以进行最先进的心脏评估。。

PrecisionCHD's ability to be administered in primary care or telemedicine settings significantly reduces the need for patients from rural communities to travel to distant specialized clinics. This accessibility marks a step towards mitigating healthcare disparities, especially in rural areas with limited resources and infrastructure.

PrecisionCHD在初级保健或远程医疗环境中进行管理的能力显着降低了农村社区患者前往远程专科诊所的需求。这种无障碍标志着向减轻医疗差距迈出了一步，特别是在资源和基础设施有限的农村地区。

Meesha Dogan Ph.D., CEO and Co-Founder of Cardio Diagnostics, emphasized, “Our commitment is to democratize access to essential cardiac care, particularly in rural areas where advanced diagnostic tools are scarce and cardiovascular specialists are even more rare. PrecisionCHD's remote accessibility and deployment capability in non-specialized settings are pivotal in achieving this goal.”.

Cardio Diagnostics首席执行官兼联合创始人Meesha Dogan博士强调：“我们的承诺是使获得基本心脏护理的民主化，特别是在先进诊断工具稀缺且心血管专家更为罕见的农村地区.PrecisionCHD的远程可访问性和非专业环境中的部署能力对于实现这一目标至关重要“。

Dr. Dogan added that “this study marks a significant step forward in CHD diagnosis, leveraging the synergies of genetics, epigenetics, and AI to offer a highly sensitive, efficient, scalable and personalized approach for CHD care.” She noted that “because the test was also recently awarded an Innovation Technology contract from Vizient, the nation’s largest group purchasing organization, clinicians at 60% of hospitals and 97% of academic medical centers in the United States already have access to the test.”.

Dogan博士补充说：“这项研究标志着冠心病诊断迈出了重要一步，利用遗传学，表观遗传学和人工智能的协同作用，为冠心病护理提供高度敏感，高效，可扩展和个性化的方法。“她指出，”因为该测试最近还获得了美国最大的集团采购组织Vizient的创新技术合同，美国60%的医院和97%的学术医疗中心的临床医生已经可以使用该测试“。

About Cardio Diagnostics

关于心脏诊断

Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease.

Cardio Diagnostics是一家由人工智能驱动的精密心血管医学公司，可使心血管疾病的预防，检测和管理更加容易，个性化和精确。该公司的成立旨在通过利用专有的人工智能（AI）驱动的心血管疾病综合遗传-表观遗传引擎（“核心技术”）进一步开发和商业化临床试验，成为改善预防的领先医疗技术公司之一，检测和治疗心血管疾病。

For more information, please visit www.cardiodiagnosticsinc.com..

欲了解更多信息，请访问www.cardiodiagnosticsinc.com。。

Forward-Looking Statements

前瞻性声明

Certain statements and information included in this press release constitute 'forward-looking statements' within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, 'will likely result,' 'expected to,' 'will continue,' 'anticipated,' 'estimate,' 'projected,' 'intend,' “goal,” or similar expressions are intended to identify 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995.

本新闻稿中包含的某些陈述和信息构成1995年“私人证券诉讼法”含义内的“前瞻性陈述”。在本新闻稿中使用时，“将会”，“可能会导致”，“预期”，“将继续”，“预期”，“估计”，“预测”，“打算”，“目标”或类似的表达旨在确定1995年“私人证券诉讼改革法”含义内的“前瞻性陈述”。

Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing.

这些陈述受到某些已知和未知的风险以及不确定性的影响，其中许多风险超出了公司的控制范围。这些不确定性和风险包括但不限于我们成功执行增长战略的能力，法律法规的变化，经济条件，对管理的依赖，对股东的稀释，缺乏资本，快速增长对公司的影响以及管理层有效应对公司产品和服务增长和需求的能力，新开发的技术，公司的竞争能力，监管事项，技术保护，竞争的影响以及公司获得未来融资的能力。

An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023 under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission.

本报告讨论了2022年12月31日结束期间的表格10-K和2023年3月31日结束期间的表格10-Q，标题为“风险因素”，其中第一部分，第一项，第一项，以及与证券交易委员会不时提交的其他文件。

Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed w.

这些因素可能会对公司的财务业绩产生重大不利影响，并可能导致公司未来期间的实际结果与w所表达的任何意见或陈述有重大差异。